Trending Now
BUSINESS
U.S. Food and Drug Administration Places Clinical Hold On Cellectis MELANI-01...
Cellectis a biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), today announced that the MELANI-01 trial has been placed...
MEDICAL DEVICES
MANUFACTURING
Helix BioPharma Corp. announces the signing of a non-binding letter of...
Helix BioPharma Corp., a clinical stage immuno-oncology company developing drug candidates for the prevention and treatment of cancer, announced that it has signed a...
DON'T MISS
JOURNAL SPOTLIGHT
‘Decorated’ Stem Cells Could Offer Targeted Heart Repair
Although cardiac stem cell therapy is a promising treatment for heart attack patients, directing the cells to the site of an injury – and...